Compare drug alternatives

Saxenda ® Alternatives

Saxenda ®(liraglutide)
Prescription Only
Saxenda (liraglutide) is used to aid weight loss and maintain weight reduction in adults dealing with obesity or overweight issues along with weight-related medical conditions....
Prescription Only
Zepbound (tirzepatide) is a medication that functions as a GIP and GLP-1 receptor agonist, aiding in weight loss for adults dealing with obesity or overweight individuals with...
Dosage & Administration
Subcutaneous. Learn more.
Subcutaneous. Learn more.
The recommended dose of SAXENDA® is 3 mg daily. Initiate at 0.6 mg per day for one week. In weekly intervals, increase the dose until a dose of 3 mg is reached.. Learn more.
Starting dosage is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase 5 mg once weekly. Increase the dosage in 2.5 mg increments after at least 4 weeks. Maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.. Learn more.
Latin Shorthand
3 mg daily. Start: 0.6 mg/day for 1 week. Weekly increments to reach 3 mg dosage.. Learn more.
The initial dose is 2.5 mg SQ q/week. After 4 weeks, increase to 5 mg q/week. Then, every 4 weeks, raise the dosage by 2.5 mg. Maintenance doses are either 5 mg, 10 mg, or 15 mg injected SQ q/week.. Learn more.
Financial Assistance
Out-Of-Pocket Costs With Copay Card
Annual Cap
$1,800. Learn more.
Assistance Expiration
12/31/2024. Learn more.
No lower-cost generic available
No lower-cost generic available
Physician Advisory
Adverse Reactions
Most common adverse reactions, reported in greater than or equal to 5% are: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, hypoglycemia, dyspepsia, fatigue, dizziness, abdominal pain, increased lipase, upper abdominal pain, pyrexia, and gastroenteritis. . Learn more.
The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease.. Learn more.
Mechanism of Actions (MoA)
GLP-1 Receptor Agonists. Learn more.
GLP-1 Receptor Agonists. Learn more.
Special Populations
Is SAXENDA® safe during pregnancy?

SAXENDA® is contraindicated during pregnancy as weight loss offers no benefit and may harm the fetus. There's limited data on its use in pregnant women.

What do animal studies reveal about liraglutide's effects during pregnancy?

Animal studies have shown increased adverse effects on embryofetal development due to liraglutide exposure during pregnancy, indicating potential harm.

Are there data on the use of SAXENDA® during lactation?

There's no data on the presence of liraglutide in human milk, but it was detected in lactating rat milk. Consider breastfeeding benefits and potential risks of SAXENDA® for both mother and infant.

Is SAXENDA® approved for pediatric use?

SAXENDA® is approved for pediatric patients aged 12 years and older with obesity, supported by clinical trials. However, some adverse events were reported in these trials.

How does SAXENDA® perform in geriatric patients?

In clinical trials, no significant differences were observed in safety or effectiveness between older and younger patients. However, caution is advised in the elderly.

What precautions should be taken for patients with renal impairment using SAXENDA®?

Limited experience exists for SAXENDA® in patients with renal impairment. There have been reports of renal failure, necessitating caution in this population.

How about the use of SAXENDA® in patients with hepatic impairment?

Limited experience exists for SAXENDA® in patients with hepatic impairment, indicating caution in this patient population.

Is SAXENDA® suitable for patients with pre-existing gastroparesis?

SAXENDA® has not been studied in patients with pre-existing gastroparesis.

Is there a pregnancy exposure registry for ZEPBOUND (tirzepatide)?

Yes, there is a pregnancy exposure registry to monitor outcomes in pregnant women exposed to ZEPBOUND. Pregnant patients and healthcare providers can contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).

What are the risks associated with ZEPBOUND during pregnancy?

Weight loss is not recommended during pregnancy and discontinuation of ZEPBOUND is advised when pregnancy is recognized. Insufficient data exist to assess the risk of birth defects or miscarriage with tirzepatide use during pregnancy. Animal studies suggest potential fetal risks with exposure to tirzepatide.

Are there clinical considerations for pregnant patients using ZEPBOUND?

Pregnant patients, including those with obesity, should gain appropriate weight as required during pregnancy. Weight loss is not advised in pregnant patients.

What animal data is available regarding tirzepatide exposure during pregnancy?

Animal studies show fetal growth reductions and abnormalities in rats and rabbits given tirzepatide during pregnancy. These effects correlated with reductions in maternal body weights and food consumption.

Is ZEPBOUND recommended during lactation?

There is no data on tirzepatide's presence in animal or human milk. The benefits of breastfeeding should be weighed against any potential adverse effects of ZEPBOUND on the breastfed infant or maternal condition.

Does ZEPBOUND impact oral hormonal contraceptives?

ZEPBOUND may reduce the effectiveness of oral hormonal contraceptives due to delayed gastric emptying. Patients using these contraceptives should consider alternative or additional contraceptive methods for specific durations.

What is known about ZEPBOUND's use in pediatric patients and the elderly?

ZEPBOUND's safety and effectiveness have not been established in pediatric patients below 18 years old. In elderly patients (65 years and older), no significant differences were observed in safety or effectiveness compared to younger adults.

Are dosage adjustments necessary for patients with renal or hepatic impairment?

No dosage adjustment is recommended for patients with renal or hepatic impairment based on clinical studies, as no significant changes in tirzepatide pharmacokinetics were observed.